News Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy Heartseed & Novo Nordisk say a patient has been successfully dosed with cell therapy HS-001.
News Novo Nordisk crowns cell therapy pipeline with $598m Heartse... Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
